Search in:

Advanced search

Expert Opinion on Drug Delivery Volume 6, 2009 - Issue 1

Submit an article Journal homepage

2,587

Views

282

CrossRef citations to date

Altmetric

Reviews

PEG-modified biopharmaceuticals

Pascal Bailon Vice President Pharmaceuticals, Quality Horizons, 21 Woodbine Road, Florham Park, NJ 07932, USA +1 973 966 1446; +1 973 966 0710; [email protected] or [email protected]

, BSc MS &

Chee-Youb Won Principal Scientist Center for Biomaterials and Advanced Technologies, Johnson & Johnson, Somerville, NJ 08876, USA

, PhD

Pages 1-16 | Published online: 09 Jan 2009

Cite this article
https://doi.org/10.1517/17425240802650568

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Harris JM, Editor, Poly(ethylene glycol) Chemistry, Biotechnical and Biomedical Applications. Plenum Press, 1992
Google Scholar
Delgado C, Francis G, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304
PubMed Web of Science ®Google Scholar
Harris JM, Zalipsky S. Editors, Chemistry and Biological Applications of Polyethylene Glycol. ACS Books, Washington DC, 1996
Google Scholar
Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998;1(8):352-6
Google Scholar
Greenwald RB, Choe YH, McGuire J, Conover D. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003;55:217-50
PubMed Web of Science ®Google Scholar
Veronese FM, Paust G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10(21):1451-8
PubMed Web of Science ®Google Scholar
Abuchowski A, McCoy TJR, Palczuk NC, Davies FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-6
PubMed Web of Science ®Google Scholar
Abuchowski A, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977;252:3578-35
PubMed Web of Science ®Google Scholar
Serruys PW, et al. Effect of an anti-PDGF-beta-receptor-blocking antibody on restenosis in patients undergoing elective stent placement. Int J Cardiovasc Intervent 2003;5(4):214-22
PubMedGoogle Scholar
Jorgensen KE, Moller JV. Use of flexible polymers as probes of glomerular pore size. Am J Physiol 1979;236: F103-11
PubMed Web of Science ®Google Scholar
Xu CZX, Rakhit A, Vonbrummelen P. PK/PD modeling approach to support clinical development of a long-acting interferon (RO-25-3036) for the treatment of hepatitis C. Hepatology 1998;28(Suppl):702A
Google Scholar
Nieforth KA, et al. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylenene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996;59(6):636-46
PubMed Web of Science ®Google Scholar
Glue P, et al. A dose ranging study of pegylated interferon alpha-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000;32(3):647-53
PubMed Web of Science ®Google Scholar
Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of Peginteferon alpha-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C. Hepatology 1999;30(Suppl):190A
Google Scholar
Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethyleneglycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994;83(4):601-6
PubMed Web of Science ®Google Scholar
Rubinstein S, et al. Convenient Assay for interferons. J Virol 1981;37:755-8
PubMed Web of Science ®Google Scholar
Bailon P, et al. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjugate Chem 2001;12:195-202
PubMed Web of Science ®Google Scholar
Zeuzem S, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Eng J Med 2000;343:1666-72
PubMed Web of Science ®Google Scholar
Heathcote EJ, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Eng J Med 2000;343:673-80
Web of Science ®Google Scholar
Bowen S, et al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Experimental Hematology 1999;27:425-32
PubMed Web of Science ®Google Scholar
Bailon P, Ehrlich GK. Innovative Drug Delivery Systems Symposium. Philadelphia, PA, 2002
Google Scholar
Westertrep-Plantenga MS, et al. Effects of weekly administration of pegylated recombinant human OB on appetite profile and energy metabolism in obese men. Am J Clin Nutr 2001;74(4):426-34
PubMed Web of Science ®Google Scholar
Layton JE, et al. Interaction of granulocyte colony-stimulating factor (G-CSF) with its receptor. J Biol Chem 1999;274(25):17445-51
PubMed Web of Science ®Google Scholar
Yuen CT, et al. Relationship between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures. Br J Haematol 2003;121(3):511-26
PubMed Web of Science ®Google Scholar
Wasley LC, et al. The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 1991;77(12):2624-32
PubMed Web of Science ®Google Scholar
Caliceti P, Veronses FM. Physico-chemical and biological properties of newpoly(ethylene glicol)-insulin conjugates. Proc Intl Symp Control Rel Bioact Mat 2000;976-7
Google Scholar
Pearce KK, et al. Growth hormone binding affinity for its receptor surpasses the requirements of cellular activity. Biochemistry 1999;38(1):81-9
PubMed Web of Science ®Google Scholar
Duncan R, Spreafico F. Polymer conjugates. Pharmacokinetic considerations or design and development. Clinical Pharmacokinet 1994;27(4):290-306
PubMed Web of Science ®Google Scholar
Knusli C, et al. Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity. Br J Haematol 1992;82(4):654-63
PubMed Web of Science ®Google Scholar
Sugiuchi H, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulphated alpha-cyclodextrin. Clin Chem 1995;41(5):717-23
PubMed Web of Science ®Google Scholar
Pettit DK, et al. Structure-function studies of interleukin 15 using site-specificmutagenesis, polyethylene glycol conjugation, and homology modeling. J Biol Chem 1997;272:2312-8
PubMed Web of Science ®Google Scholar
Yowell SL, Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat Rev 2002;(Suppl A):3-6
PubMed Web of Science ®Google Scholar
Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23(8 pt 2):3S-8S
PubMed Web of Science ®Google Scholar
Digilio G, et al. NMR Structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2. J Am Chem Soc 2003;125:3458-70
PubMed Web of Science ®Google Scholar
Youngster S, et al. Structure, biology and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des 2002;8(240):2139-57
PubMed Web of Science ®Google Scholar
Wang YS, et al. Structural and biological characterization of pegylated recombinant interferon alph-2b and its therapeutic implications. Adv Drug Deliv Rev 2002;54(4):547-70
PubMed Web of Science ®Google Scholar
Hinks KD, Kim SW. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 2002;54(4):505-30
PubMed Web of Science ®Google Scholar
Dhalluin C, et al. Structural and biophysical characterization of the 40 kDa PEG-Interferon-α2a and its individual positional isomers. Bioconjg Chem 2005;16:504-17
PubMed Web of Science ®Google Scholar
Kinstler OB, et al. Characterization and stability of N–terminally PEGylated rhG- CSF. Pharm Res 1996;13(7):996-1002
PubMed Web of Science ®Google Scholar
Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003;55(10):1261-77
PubMed Web of Science ®Google Scholar
Yamaoka T, Tabata Y, Ikada Y. Fate of water-soluble polymers administered via different routes. J Pharm Sci 1995;84(3):349-54
PubMed Web of Science ®Google Scholar
Veronese FM, et al. Preparation, physico-chemical and pharmacokinetic characterization of monomethoxypoly(ethylene glycol)-derivatized superoxide dismutase. J Contr Rel 1989;10:145-54
Web of Science ®Google Scholar
Caliceti P, Schiavon O, Veronese FM. Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers. Bioconjug Chem 1999;10(4):638-46
PubMed Web of Science ®Google Scholar
Maeda H, Kono T. Tumor-targeted chemotherapy with lipid contrast medium and macromolecular anticancer agents theoretical consideration and clinical outcome. Gan To Kagaku Ryoho 1985;12(3 pt 2):273-82
Google Scholar
Maeda H, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. A review. J Contr Rel 2000;65:271-84
PubMed Web of Science ®Google Scholar
Luo Y, Prestwich GD. Cancer-targeted polymeric drugs. Current Cancer Drug Targets 2002;2:209-26
PubMed Web of Science ®Google Scholar
Murakami Y, et al. Tumor accumulation of poly(ethylene glycol) with different molecular weights after i.v. injection. Drug Del 1997;4:23-32
Web of Science ®Google Scholar
Fang J, et al. Factors and mechanism of ‘EPR’ effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 2003;519:29-49
PubMed Web of Science ®Google Scholar
Caliceti P, et al. Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor targeting. J Contr Rel 2002;83:97-108
PubMed Web of Science ®Google Scholar
Cheng TL, et al. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylenene glycol IgM. Biconjug Chem 1999;10(3):520-8
PubMed Web of Science ®Google Scholar
Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 2002;54:531-45
PubMed Web of Science ®Google Scholar
King DJ, Adair JR. Recombinant antibodies for the diagnosis and therapy of human diseases. Curr Opin Drug Discov Dev 1999;2:110-7
PubMedGoogle Scholar
Walsh G. Biopharmaceuticals bench marks. Nat Biotechnol 2000;18:831-3
PubMed Web of Science ®Google Scholar
Suzuki T, et al. Physicochemical and biological properties of poly(ethylene glycol)- coupled immunoglobulin G. Biochim Biophys Acta 1984;788:248-55
PubMed Web of Science ®Google Scholar
King DJ, et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994;54:6176-85
PubMed Web of Science ®Google Scholar
Chapman AP, et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999;17:780-3
PubMed Web of Science ®Google Scholar
Albrecgt H, et al. Production of soluble ScFvs with C-terminal-free thiol for site- specific conjugation or stable dimeric ScFvs on demand. Bioconjugate Chem 2004;15:16-26
PubMed Web of Science ®Google Scholar
Natarajan A, et al. Characterization of site-specific ScFv PEGylation for tumor- targeting pharmaceuticals. Bioconjugate Chem 2005;16:113-21
PubMed Web of Science ®Google Scholar
Yang K, et al. Tailoring structure function and pharmacokinetic properties of single- chain Fv site-specific PEGylation. Protein Engineering 2003;16(10):761-70
PubMedGoogle Scholar
Peddley RB, et al. The potential for enhanced tumor localization by poly(ethylene glycol) modification of an anti-CEA antibody. Br J Cancer 1994;70:1126-30
PubMed Web of Science ®Google Scholar
Casey JL, et al. Improved tumor targeting of di-Fab' fragments modified with polyethylene glycol. Tumor Target 2000;4:235-44
Google Scholar
Lee LS, et al. Prolonged circulating lives of single chainFv proteins conjugated with polyethylene glycol: A comparison of conjugation chemistries and compounds. Bioconjug Chem 1999;10:973-81
PubMed Web of Science ®Google Scholar
Monfardini C, et al. A branched monomethoxy poly(ethylene glycol) for protein modification. Bioconjug Chem 1995;6:62-9
PubMed Web of Science ®Google Scholar
Greenwald RB, Martinez AJ. Non-antigenic branched polyme conjugates US5919455; 1999
Google Scholar
Zalipsky S. Functionalized poly(ethylene glycol) for preparation of biologically Relevant Conjugates. Bioconjug Chem 1995;6:150-65
PubMed Web of Science ®Google Scholar
Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002;54(4)459-76
PubMed Web of Science ®Google Scholar
Morpurgo M, Veronese FM. Conjugates of peptides and proteins to polyethylene glycols. Methods Mol Biol 2004;283:45-70
PubMedGoogle Scholar
Abuchowski A, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984;7(2):175-86
PubMedGoogle Scholar
Harris JM, et al. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications. US5672662; 1997
Google Scholar
Greenwald RB, Martinez AJ. Cyclic imide thione activated polyalkylene oxides US5405877; 1995
Google Scholar
Elling L, Kula MR. Immunoaffinity partitioning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies. Biotechnol Appl Biochem 1991;13(3):354-62
PubMed Web of Science ®Google Scholar
Beauchamp CO, et al. A new procedure for the synthesis of polyethylene glycol- protein adducts; effects on function, receptor recognition and clearance of superoxide dismutase, lactoferin and alpha 2-macroglobulin. Anal Biochem 1983;131(1):25-33
PubMed Web of Science ®Google Scholar
Delgado C, et al. Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotechnol Appl Biochem 1990;12(2):119-28
PubMed Web of Science ®Google Scholar
Zalipsky S. Active carbonates of polyalkylene oxides for modification of polypeptides. US5122614; 1992
Google Scholar
Veronese FM, et al. Surface modification of proteins. Activation of monomethoxy- polyethylene glycols by phenyl chloroformates and modification of ribonuclease and superoxide dismutase. Appl Biochem Biotechnol 1985;11(2):141-52
PubMed Web of Science ®Google Scholar
Dolence EK, et al. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces. US5650234; 1997
Google Scholar
Harris JM, et al. Preparation and use of polyethylene glycol propionaldehyde. US5252714; 1993
Google Scholar
Bentley MD, Harris JM. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines. US5990237; 1999
Google Scholar
Davies FF, et al. Non-immunogenic polypeptides. US4179337; 1979
Google Scholar
Greenwald RB, et al. Highly water soluble taxol derivatives: 7-Polyethylene glycol carbamates and carbonates. J Org Chem 1995;60:331-6
Web of Science ®Google Scholar
Goodson RJ, Katre NV. Site-directed PEGylation of recombinant interleukin-2 at its glycosylation site. Bio/Technol 1990;8:343-6
PubMed Web of Science ®Google Scholar
Morpurgo M, et al. Preparation of characterization of poly(ethylene glycol) vinyl sulfone. Bioconjug Chem 1996;7(3):363-8
PubMed Web of Science ®Google Scholar
Shearwater Polymers. Quarterly Newsletter. 1998
Google Scholar
Woghiren C, et al. Protected thiol-polyethylene glycol: a new activated polymer for reversible protein modification. Bioconjug Chem 1993;4(5):314-8
PubMed Web of Science ®Google Scholar
Filpula D, Zhao H. Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev 2008;60(1):29-49
PubMed Web of Science ®Google Scholar
Zalipski S, et al. New detachable polyethylene glycol conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipids. Bioconjug Chem 1999;10:703-10
PubMed Web of Science ®Google Scholar
Greenwald RB, et al. Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination. Bioconjug Chem 1999;14(2):395-403
Web of Science ®Google Scholar
Greenwald RB, et al. A new aliphatic prodrug system for the delivery of small molecules and proteins utilizing novel PEG derivatives. J Med Chem 2004;47(3):726-34
PubMed Web of Science ®Google Scholar
Shecter Y, et al. Reversible PEGylation of insulin facilitates its prolonged action in vivo. Eur J Pharm and Biopharm 2008; In Press
Google Scholar
Peleg-Shulman T, et al. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J Med Chem 2004;47(20):4897-490
PubMed Web of Science ®Google Scholar
Porter J, et al. Symposium on recovery of biological products VIII, Div of Biochem Technol Tuscon, AZ, 1996
Google Scholar
Parkins DA, Lashmar TU. The formulation of biopharmaceutical products. PSTT 2000;3(4):129-34
PubMedGoogle Scholar
Krishnan S. Formulation Development for PEGylated Biopharmaceuticals. AAPS Short course on Development of PEGylated Biopharmaceuticals Handbook 2005;57-78
Google Scholar
Piedmonte DM, Treuheit JM. Formulation of Neulasta® (pegfilgrastim). Adv Drug Deliv Rev 2008;60(1):50-8
PubMed Web of Science ®Google Scholar
Zoon K. Well-Characterized Biological Products (WCBP), Joint Meeting of FDA and Industry, Washington, D.C., USA, 1999
Google Scholar
Monkarsh SP, et al. Positional isomers of monopegylated interferon α-2a: Isolation, characterization and biological activity. Anal Biochem 1997;247:434-40
PubMed Web of Science ®Google Scholar
Grace M, et al. Structural and biologic characterization of pegylated recombinant interferon α-2b. J Interferon and Cytokine Res 2001;21:1103-15
PubMed Web of Science ®Google Scholar
Lee H, Park G. A novel method for identifying PEGylation sites of protein using biotinylated PEG derivatives. J Pharma Sci 2003;92(1):97-103
PubMed Web of Science ®Google Scholar
Foser S, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a. J Prot Exp Purif 2003;30:78-87
PubMed Web of Science ®Google Scholar
Fung WJ, et al. Strategies for the preparation and characterization of polyethylene glycol (PEG) conjugated pharmaceutical proteins. Polym Prepr 1997;38:565-6
Google Scholar
Bailon P. The potential role of PEG-modified biopharmaceuticals in the emerging global biosimilar market. International Biotechnology Symposium. Dalian, China, 2008
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

PEG-modified biopharmaceuticals

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

PEG-modified biopharmaceuticals

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date